EyePoint Pharmaceuticals’ EYP-1901: Promising Novel Drug Delivery System

ByJoshua Mali, MD

In this episode, I chat with Nancy Lurker, CEO and board director, about EyePoint Pharmaceuticals and their latest treatments and trials.

Brought to you by Alcon

Welcome to another exciting episode of Eye Care insider :13
Intro Nancy Lurker :22
Lurker’s background :58
EyePoint Pharmaceuticals: the origin and transition 2:29
Yutiq and long-acting drug delivery systems 6:07
Additional indications for Yutiq 8:30
What is the key factor in delivering this longer durability? 16:13
Any consideration of looking at superiority of visual acuity and anatomical OCT gains? 21:47
Is the primary focus wet AMD? Or are you also looking at NPDR and DME as potential indications? 24:19
Investor information and neural protection data 29:01
What is the most important issue that the field of ophthalmology is currently facing? 30:38
Thanks for listening 32:37

We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. You can find Nancy Lurker at @EyePointCEO and @EyePointPharma.

Nancy Lurker is the board director and CEO of EyePoint Pharmaceuticals.

Published by:

Sources/Disclosures

Collapse

Disclosures: Lurker is the board director and CEO of EyePoint Pharmaceuticals. Mali reports he is founder and CEO of Mali Enterprises; consultant/speaker for Genentech and Roche; equity owner for SNAPS; and grant/consultant for RetinAI.

Read more

EyePoint Pharmaceuticals’ EYP-1901: Promising Novel Drug Delivery System

Eye Care Insider

Related Content